Prostate Cancer Foundation Scientific Retreat | Conferences

Preliminary Safety and Efficacy Results Observed for AMG 160 in mCRPC

October 23, 2020

The bispecific T‐cell engager, AMG 160, demonstrated a manageable safety profile and preliminary evidence of efficacy in heavily pretreated patients with metastatic castration-resistant prostate cancer in a 2-part, phase 1 open-label study.

AR/AKT Combination Bests AR Blockade in mCRPC with PTEN Loss

October 23, 2020

The combination of ipatasertib and abiraterone acetate achieved a significantly superior radiographic progression-free survival and demonstrated anti-tumor activity compared with placebo and abiraterone in patients with metastatic castration resistant prostate cancer with PTEN loss, according to results from the phase 3 IPATential150 clinical trial.

PSMA-Targeted Therapies in Clinical Development Show Promise for Prostate Cancer

October 23, 2020

Naomi Haas, MD, discusses several areas of interest for the treatment of patients with prostate cancer that are utilizing PSMA, including bispecific T-cell engager antibodies, chimeric antigen receptor T cells, and the lutetium studies.

VERU-111 Shows Early Promise and Safety in mCRPC After Progression on AR Therapy

October 22, 2020

A novel tubulin inhibitor VERU-111 has demonstrated promising early antitumor activity and tolerability in men with metastatic castration-resistant prostate cancer who have failed prior androgen receptor therapy, according to the results of a phase 1b/2 study.

BXCL701 Split Dosing Improves Tolerability in Metastatic Castration-Resistant Prostate Cancer

October 22, 2020

Split-dosing of BXCL701 at 0.6 mg per day is a supported dosing strategy for the agent in combination with pembrolizumab as treatment of patients with metastatic castration-resistant prostate cancer, according to phase 1b/2 study results.

PLK1 Inhibitor, Abiraterone Combo Shows Preliminary Efficacy and Safety in mCRPC

October 22, 2020

In a phase 2 trial, onvansertib, a polo-like kinase 1 inhibitor, combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer who have early abiraterone resistance, demonstrated a decent safety profile across 3 dosing schedules and efficacy in the evaluable arms.